Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q1 2020 · 10-Q
Revenue$101.83M$101.83M+38.9% vs Q1 2019 Net Income$3.95M$3.95MN/M vs Q1 2019 EPS Diluted$0.04$0.04N/M vs Q1 2019 Gross Profit$77,332,000+44.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$1,957,000N/M Free Cash Flowderived-$1,155,000N/M Margins · derivedGross margin75.9%+3.0 pt vs Q1 2019
Operating margin-3.3%+5.0 pt vs Q1 2019
Net margin3.9%+20.5 pt vs Q1 2019
ended Mar 31, 2020 · filed Apr 30, 2020 · 30 d after period end